Company: PGEN
Filing Date: 2025-11-13
Form Type: 10-Q
Source: 0001356090-25-000034
Chunk: 161

Company: PRECIGEN, INC.
Filing Date: 2025-11-13
Form: 10-Q
Item: Part I, Item 2
Chunk 161
---
mergers and similar transactions, (vii) restrictions on amendments to organizational documents and material contracts, in each

case subject to specified exceptions, (viii) minimum net sales and (ix) minimum liquidity. The Loan Agreement also contains customary representations and warranties, including, without limitation, with respect to (i) organization, authority and

enforceability, (ii) financial condition, (iii) compliance with laws, (iv) intellectual property and regulatory matters, and (v) the

absence of a material adverse change.

Our indebtedness could also have important negative consequences for our security holders and our business, results of

46

operations and financial condition, including:

• we will need to repay the indebtedness by making payments of interest and principal, which will reduce the amount of

cash available to finance our operations, our research and development efforts and other general corporate activities;

•our failure to comply with the obligations of our affirmative and restrictive covenants in the Loan Agreement could

result in an event of default that, if not cured or waived, would permit the Lenders to accelerate our obligation to repay

this indebtedness, and the Lenders could seek to enforce their security interest in the assets securing such indebtedness;

and

•we may be more vulnerable to downturns in our business, our industry or the economy in general.

In addition, we may borrow additional capital in the future to fund clinical development and our future growth, including

pursuant to the Loan Agreement or potentially pursuant to new arrangements with different lenders. To the extent additional

debt is added to our current debt levels, the risks described above could increase.